EIC Accelerator
Also known as: European Innovation Council Accelerator, EIC, SME Instrument (predecessor)
EU funding programme offering blended finance (grant up to €2.5M plus equity up to €15M) for high-potential SMEs with breakthrough innovations. Highly competitive; relevant for EU-based HealthTech and Digital Medicine companies at Seed+ and Series A stage.
Full Definition
The EIC Accelerator is a European Innovation Council programme that provides blended finance — a combination of a non-dilutive grant component (up to €2.5M) and an equity investment component (up to €15M) — to high-potential SMEs developing breakthrough innovations with potential for scale. The total award can reach up to €17.5M. Companies can apply for grant-only or blended finance.
Within the GAITS Funding Readiness Framework, the EIC Accelerator is most relevant at Seed+ and Series A stage for both HealthTech and Digital Medicine companies. It is highly competitive — acceptance rates are typically below 5% — and the evaluation process is rigorous, requiring a written proposal, a pitch, and a panel interview. The EIC looks for innovations with genuine market-creating potential, not incremental improvements.
Companies must be based in an EU member state or associated country. The equity component is taken by the EIC Fund, which is a patient, minority investor. EIC Accelerator funding is often used alongside private venture capital. Teams should note that the process is lengthy (6–12 months) and requires strong commercial as well as technical evidence.
A Danish medical device startup has CE-marked a novel implantable cardiac monitor and completed a 150-patient clinical study showing superiority to current standard of care. They apply for EIC Accelerator blended finance: €2.5M grant plus €10M equity. The grant funds a pan-European clinical registry and reimbursement submissions in three markets; the equity funds the commercial team build-out. The EIC Fund takes a minority equity position alongside two lead VCs. The blended structure allows the team to reduce dilution while accessing the scale capital needed for a Series A-equivalent funding round.